From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...

The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates ...

CRISPR Therapeutics, co-developer of the CASGEVY gene-editing cure for sickle cell disease and beta-thalassemia, was added to ...

CRISPR Therapeutics draws attention as healthcare strength and gene-editing innovation keep the biotech name in market focus.

Vertex Pharmaceuticals recently reported Phase 3 data showing that its CRISPR-based therapy CASGEVY delivered strong clinical ...

Q: I have genetically caused high LDL cholesterol — it hit 200 mg/dL before I started treatment with atorvastatin and ...

Researchers found that prucalopride, a drug used to treat chronic constipation, improved verbal memory and processing speed ...

Q: I know vision and hearing can fade with age, but lately I seem to have less ability to smell things, from flowers to ...

Intellia unveiled additional Phase 3 data for its CRISPR-based HAE treatment, Lonvo-z.

Novel in vivo CRISPR-based therapy lonvoguran ziclumeran (lonvo-z) dramatically lowered hereditary angioedema (HAE) attack ...

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy.

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology ...